You are here: Urology Textbook > Drugs in Urology > Alpha blocker > Tamsulosin
Alpha Blocker Tamsulosin: Side Effects and Dosage
- Alpha blockers: General pharmacology
- Alpha blocker Alfuzosin
- Alpha blocker Doxazosin
- Alpha blocker Silodosin
- Alpha blocker Tamsulosin
- Alpha blocker Terazosin
Mechanism of Action of Tamsulosin
Tamsulosin is a selective α1A and α1D blocker with a long half-life and favorable cardiovascular side effects. Please see section general pharmacology of alpha blocker.
Indications for Tamsulosin
- Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
- Off-label treatment of female LUTS due to neurogenic bladder neck obstruction.
- Off-label treatment: improve the spontaneous passage of distal ureteral stones.
Pharmacokinetics of Tamsulosin
- Elimination half-life 12 h
- The OCAS-preparation (Oral Controlled Absorption System) allows a single daily dosing.
Side Effects of Tamsulosin
Decreased side effect profile since tamsulosin is a selective α1A and α1D blocker.
- Hypotension, orthostatic syncope, reflex tachycardia
- Stuffy nose
- Retrograde ejaculation
- Dizziness, weakness
- Overall rate of side effects is between 10–30%.
Contraindications of Tamsulosin
Conservative treatment of BPH with tamsulosin is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.
Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.
Tamsulosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.
Dosage of Tamsulosin
0.4 mg orally once daily.
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Chapple 2004 CHAPPLE, C. R.:
Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
M. G. Lucas, T. P. Stephenson, and V. Nargund, “Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia,” BJU Int, vol. 95, no. 3, pp. 354–7, 2005.
M. Oelke and FranÃ, “Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.,” Eur. Urol., vol. 61, no. 5, pp. 917–925, 2012.
Deutsche Version: Tamsulosin